Management of adult patients with ascites due to cirrhosis: An update
Bruce A. Runyon – 28 May 2009
Methodological reporting of randomized clinical trials in major gastroenterology and hepatology journals in 2006
Yu Bai, Jun Gao, Duo‐Wu Zou, Zhao‐Shen Li – 28 May 2009 – To determine the current quality of reporting of randomized clinical trials (RCTs) in the field of gastroenterology and hepatology, we evaluated the methodological reporting of RCTs in six major gastroenterology and hepatology journals.
Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time
Dar‐In Tai, Shi‐Ming Lin, I‐Shyan Sheen, Chia‐Ming Chu, Deng‐Yn Lin, Yun‐Fan Liaw – 28 May 2009 – The baseline alanine aminotransferase (ALT) level was reported to have prognostic value in chronic hepatitis B virus (HBV) infection, during which ALT may change over time. Instead of baseline ALT, this study aimed to study the prognostic value of the height of ALT during the course of chronic HBV infection.
Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis
Shannon S. Glaser, Gianfranco Alpini – 28 May 2009
Reply:
Zigmund Luka, M. Luz Martínez‐Chantar, Shelly C. Lu, Conrad Wager, José M. Mato – 28 May 2009
Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation
Emilio Fábrega, Marcos López‐Hoyos, David San Segundo, Fernando Casafont, Fernando Pons‐Romero – 28 May 2009 – Interleukin‐23 (IL‐23) and T helper 17 (Th17) cells have been cast as major players in autoimmunity, but their role in transplantation immunity remains to be specified. The aim of our study was to investigate the time course of serum levels of IL‐23 and IL‐17 during hepatic allograft rejection. Serum levels of IL‐23 and IL‐17 were determined in 20 healthy subjects and 50 hepatic transplant recipients.
Long‐term follow‐up of donor chimerism and tolerance after human liver transplantation
Rosa Ayala, Silvia Grande, Enriqueta Albizua, Almudena Crooke, Juan Carlos Meneu, Almudena Moreno, Baltasar Pérez, Florinda Gilsanz, Enrique Moreno, Joaquín Martínez‐Lopez – 28 May 2009 – We aimed to quantify peripheral donor chimerism (DC) and to analyze its association with graft and recipient outcome. Forty‐two liver transplant recipients and their respective donors were studied, providing a total of 148 posttransplantation serum samples. DC was assessed with real‐time quantitative polymerase chain reaction (qPCR) to detect polymorphic markers.
Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor β actions in hepatocytes—But without modulating bone morphogenetic protein 7 signaling
Olav A. Gressner, Birgit Lahme, Monika Siluschek, Katharina Rehbein, Ralf Weiskirchen, Axel M. Gressner – 28 May 2009 – In vivo knockdown of connective tissue growth factor (CTGF/CCN2) was recently shown to attenuate the formation of experimental liver fibrosis.
SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C
Giada Sebastiani, Philippe Halfon, Laurent Castera, Stanislas Pol, David L. Thomas, Alessandra Mangia, Vito Di Marco, Mario Pirisi, Mihai Voiculescu, Maria Guido, Marc Bourliere, Franco Noventa, Alfredo Alberti – 28 May 2009 – The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use.